Tate & Lyle plc (LON:TATE – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 647.05 ($8.66) and traded as high as GBX 670.50 ($8.98). Tate & Lyle shares last traded at GBX 665 ($8.90), with a volume of 384,147 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank reissued a “buy” rating and issued a GBX 860 ($11.52) price objective on shares of Tate & Lyle in a report on Wednesday, May 29th.
Read Our Latest Research Report on TATE
Tate & Lyle Price Performance
Insider Buying and Selling
In other news, insider Jeffrey Carr purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was purchased at an average cost of GBX 624 ($8.36) per share, with a total value of £62,400 ($83,556.51). In other Tate & Lyle news, insider David Hearn bought 15,500 shares of the stock in a transaction on Wednesday, August 21st. The shares were bought at an average price of GBX 655 ($8.77) per share, with a total value of £101,525 ($135,946.71). Also, insider Jeffrey Carr purchased 10,000 shares of Tate & Lyle stock in a transaction dated Wednesday, July 17th. The stock was bought at an average cost of GBX 624 ($8.36) per share, with a total value of £62,400 ($83,556.51). 2.19% of the stock is owned by corporate insiders.
Tate & Lyle Company Profile
Tate & Lyle PLC, together with its subsidiaries, provides ingredients and solutions to the food, beverage, and other industries in the United States, the United Kingdom, other European countries, and internationally. It operates through three segments: Food & Beverage Solutions, Sucralose, and Primary Products.
Featured Articles
- Five stocks we like better than Tate & Lyle
- Stock Splits, Do They Really Impact Investors?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is a Secondary Public Offering? What Investors Need to Know
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Dividend Payout Ratio Calculator
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Tate & Lyle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tate & Lyle and related companies with MarketBeat.com's FREE daily email newsletter.